BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Mallinckrodt
McKesson
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Daiichi Sankyo
Express Scripts
Healthtrust
Dow

Generated: January 16, 2018

DrugPatentWatch Database Preview

Claims for Patent: 5,260,301

« Back to Dashboard

Summary for Patent: 5,260,301
Title: Pharmaceutical solution containing FK-506
Abstract:A pharmaceutical solution which contains the compound of the general formula having the immusuppreseive activity is disclosed. ##STR1##
Inventor(s): Nakanishi; Shigeo (Neyagawa, JP), Yamanaka; Iwao (Osaka, JP)
Assignee: Fujisawa Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:07/984,239
Patent Claims: 1. A pharmaceutical solution which comprises FK 506, a pharmaceutically acceptable surface active agent comprising polyoxyethylene hydrogenated castor oil, and a pharmaceutically acceptable nonaqueous solvent selected from the group consisting of ethanol, pyropylene glycol, glycerin and polyethylene glycol.

2. The pharmaceutical solution of claim 1, wherein the FK 506 and the pharmaceutically acceptable surface active agent are in the ratio of 1:1 to 1:100 by weight.

3. The pharmaceutical solution of claim 1, wherein the pharmaceutically acceptable nonaqueous solvent is propylene glycol.

4. The pharmaceutical solution of claim 1, wherein the pharmaceutically acceptable nonaqueous solvent is glycerin.

5. The pharmaceutical solution of claim 1, wherein the pharmaceutically acceptable nonaqueous solvent is polyethylene glycol.

6. The pharmaceutical formulation of claim 1, wherein the polyoxyethylene hydrogenated castor oil is polyoxyethylene hydrogenated Castor Oil 60.

7. The pharmaceutical solution of claim 1 wherein the pharmaceutically acceptable nonaqueous solvent is ethanol.

8. A process for preparing a pharmaceutical solution, which comprises mixing FX 506 and a pharmaceutically acceptable surface active agent comprising polyoxyethylene hydrogenated caster oil in a pharmaceutically acceptable nonaqueous solvent selected from the group consisting of ethanol, propylene glycol, glycerin and polyethylene glycol.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Cipla
Covington
Cerilliant
Deloitte
Queensland Health
Johnson and Johnson
Farmers Insurance
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot